Yesafili

Yesafili (aflibercept) is an intravitreal injection used to treat retinal conditions like wet age-related macular degeneration and diabetic macular edema. This biosimilar offers a cost-effective alternative for eye health support. Suitable for patients seeking reliable retinal therapy. EU-sourced for quality assurance.

Yesafili (aflibercept) is prescribed to slow vision loss in adults with wet age-related macular degeneration by targeting abnormal blood vessel growth. It also helps manage diabetic macular edema by reducing fluid leakage in the retina. This intravitreal therapy supports retinal health in patients with these conditions. Always consult a healthcare provider for suitability.

After injection, aflibercept works locally in the eye to inhibit vascular endothelial growth factor, which may reduce swelling and leakage. Patients often report stabilized or improved vision over time with regular treatment. Eye discomfort or redness may occur temporarily post-injection.

Store Yesafili refrigerated and protect from light until use. Avoid contamination by using sterile techniques during administration. Patients with eye infections or active inflammation should discuss risks with their doctor. Keep out of reach of children and pets.

No known drug interactions exist for aflibercept when used as directed intravitreally. However, other eye medications should be administered separately to avoid dilution effects. Always inform your healthcare provider about all medications, including over-the-counter products.